Inocras and Summit Pharmaceuticals International Corporation Join Forces to Advance Healthcare in Japan
Shots:
- Inocras & Summit Pharmaceuticals have partnered to explore the commercialization of whole genome sequencing (WGS) analysis services. The alliance will utilize genomic data & bioinformatics to improve the understanding of treatment for cancer & genetic disorders in Japan
- Inocras will use its bioinformatics platform to convert WGS data into actionable clinical insights for precise diagnoses and personalized treatments
- Both the companies will form a business plan by evaluating market potential, operational models & clinical impact, with contribution from KOLs, to incorporate WGS into Japan’s healthcare system. A WGS lab will be set up to improve local bioinformatics capabilities
Ref: PR Newswire | Image: Inocras & Summit Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
